TrialNCT06043323
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
- Last update posted
- 09/04/2026
- Start
- 01/08/2024
- Sponsor
- M.D. Anderson Cancer Center
- Specialties
- oncology
Conditions: Follicular Lymphoma
Brief summary
To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.